Abstract
Supplementary Figure S2 shows that inactivation of the N-terminal EGFR kinase domain only partially abrogates the tumorigenicity of EGFR-SHC1, as demonstrated by soft agar colony formation assays. It also presents dose-response curves comparing the sensitivity of EGFR-RAD51 and EGFR-SHC1 to three EGFR-TKIs, along with immunoblotting analyses of downstream signaling inhibition following TKI treatment.